Capsovision, INC 8-K filings

CapsoVision Inc. announced the appointment of Dr. David S. Shields to its Board of Directors, effective July 1, 2026, succeeding Dr. Joanne Imperial who will continue as a consultant.

CapsoVision, Inc. stockholders re-elected three Class I Directors and ratified the appointment of Baker Tilly US, LLP as the independent auditor for fiscal year 2026.

CapsoVision announced its first quarter 2026 financial results, reporting stable revenue of $2.8 million, while highlighting progress on its AI-assisted reading feature and pipeline development.

CapsoVision announced a $14 million private placement, preliminary Q4 and full-year 2025 financial results, and updates on its CapsoCam Colon and pancreatic cancer detection programs.

CapsoVision, Inc. amended its development agreement with Canon Inc., increasing the total fee by $1 million for enhanced CMOS image sensor features.

CapsoVision, a medical technology company, announced the submission of its AI-assisted module for CapsoCam Plus to the FDA for 510(k) clearance, aiming to enhance diagnostic capabilities and reduce clinician review time.

CapsoVision reported a 19% revenue increase in Q3 2025, driven by strong CapsoCam Plus sales, while advancing AI and pancreatic cancer detection initiatives.

CapsoVision, Inc. has submitted an application to the FDA for Breakthrough Device Designation for its CapsoCam UGI capsule endoscopy system for early pancreatic cancer detection.

CapsoVision, Inc. announced the appointment of David Garcia, a seasoned finance executive, as its new Senior Vice President of Finance, Principal Financial Officer, and Principal Accounting Officer, effective November 3, 2025.

CapsoVision, Inc. announced the planned retirement of its Senior Director of Clinical Affairs, Rebecca Petersen, and the promotion of Keri Jorgenson to Director of Clinical Operations, effective October 15, 2025.

CapsoVision, Inc. announced the departure of Chief Financial Officer Kevin Lundquist, effective August 27, 2025, initiating a search for his successor.

CapsoVision announced a 17% increase in second quarter 2025 revenue, driven by increased CapsoCam Plus sales and new account growth, alongside a successful initial public offering.

CapsoVision, Inc. announced a strategic development agreement with Canon Inc. for advanced image sensors for future capsule endoscopies and completed an overallotment exercise from its recent IPO, raising an additional $600,000.

CapsoVision, Inc., a medical technology company, successfully closed its initial public offering, raising $27.5 million in gross proceeds by selling 5,500,000 shares of common stock at $5.00 per share.